Business Wire

SEOUL-VIOSYS

29.12.2022 15:01:37 CET | Business Wire | Press release

Share
Seoul Viosys: Through Air Purifier and Air Sterilizer Filters, Bacterial Growth and Leakage Occur

Seoul Viosys (“SVC”) (KOSDAQ: 092190), a global optical semiconductor company, conducted a test on air sterilization by air purifiers sold in the market. The test confirms that bacterial growth and its leakage occur through the filters. The Company announced filters in air purifiers and air sterilizers can cause viral infection and virus spread.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221229005046/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

[Figure 1] In-house bacterial culture measurement lab (left) in Seoul Viosys, and result of residual bacteria counting within filters (right) (Graphic: Business Wire)

The Company commissioned a research institute K, an internationally certified testing and research institute, to conduct a ‘test on bacterial residue count’ to check how many germs remain within filters. Air purifiers sold in the market were randomly selected and the filter contamination level was checked. For one gram of filter, an average of 70 CFU (colony forming unit) was confirmed, and for yeast and mold, more than 300 CFU per gram. These numbers are three times higher than the bacteria-permissible level, 100 CFU/g, in wet tissues under the current Cosmetics Act of Korea.

In general, air purifier filters need to be replaced, on a regular basis, every 6 months or every year, as the capture performance of filters is compromised due to suspended particles such as captured dust. According to a thesis on the survival period of harmful bacteria in filters (Survival of Microorganisms on HEPA Filters. James T. Walker et al., Applied Biosafety Vol. 16, No. 3, 2011), it has been confirmed that Staphylococcus epidermidis which causes vomiting, stomachache, and diarrhea can live up to five days in filters, and Bacillus atrophaeus can survive for more than 6 days up to 210 days at maximum.

The Bioresearch team of the Company checked bacterial residue inside filters, and then based on the outcome, the team also conducted a ‘virus filtration test (virus passage test).’ After spraying ‘Phi X 174’ virus which is similar to the Covid-19 virus in size and features at a chamber of 60 m3, air purifiers from Company A, B, and C were operated for 10 minutes, respectively. Then, the virus level was measured around the purifier’s outlet area, and virus level was confirmed at 0.005~0.01% compared to the sprayed virus concentration in the air. One virus can multiply up to 1 million to 100 million times at maximum in 5~6 hours, and even if air purifier filter is used, 10,000 viruses, amounting to 0.01%, may not be filtered and may disperse into the air. Usually, as a small number of viruses such as 1,000 flu (influenza) viruses and 10~100 Noroviruses can cause infection, a sterilization system to prevent any micro leakage is required. It has been measured that one droplet of a Covid-19 patient contains 100-1,000 viruses at maximum.

Young Ju Lee, CEO of Seoul Viosys Co., Ltd. said, “Through this test, it has been confirmed that as time goes by, filters can even work as a medium of bacteria growth, and viruses that pass the filter can spread the infection. Filters alone cannot prevent bacterial infection and sterilization will be the best way for disinfection.”

With its dedication to UV LED technology development for the last 20 years, the Company has developed a clean sterilization technology, ‘Violeds.’ As part of the activities to prevent the spread of infection through the air, in 2020, the Company has provided ‘air sterilizers’ for free in 300 SOHO business sites in Korea that combine filters with ‘Violeds’ technology, developed based on the investment of KRW one billion. According to a phone survey on its users in December 2022, 92% of respondents were found to be satisfied, and 83% said they would recommend the product to others, showing that the level of satisfaction with the product is quite high.

About Seoul Viosys

Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “WICOP Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2018). Seoul Viosys has an extensive UV LED portfolio with all wavelengths range (200nm to 1600nm) including ultraviolet rays (UV), visible rays and infrared rays. It holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for strong sterilization and disinfection (UVC), skin regeneration (UVB), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add the advanced VCSEL technology which supports smartphone facial recognition and autonomous driving, and has started its mass production. In January 2020, it introduced a disruptive “WICOP Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/, YouTube, Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221229005046/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye